Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort

详细信息    查看全文

• 作者：S. Bacon ; M. P. Kyithar ; S. R. Rizvi ; E. Donnelly ; A. McCarthy ; M. Burke ; K. Colclough ; S. Ellard and M. M. Byrne
• 刊名：Diabetic Medicine
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：33
• 期：7
• 页码：976-984
• 全文大小：183K
• ISSN：1464-5491

文摘

m>HNF1Am> gene mutations are the most common cause of maturity-onset diabetes of the young (MODY) in the UK. Persons with HNF1A–MODY display sensitivity to sulphonylurea therapy; however, the long-term efficacy is not established. There is limited literature as to the prevalence of micro- and macrovascular complications in this unique cohort. The aim of this study was to determine the natural progression and clinical management of HNF1A–MODY diabetes in a dedicated MODY clinic.